| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 10% | +100% | $652,925 | +$380,336 | 717,500 | +140% | Armistice Capital, LLC | 31 Mar 2025 |
As of 30 Sep 2025, 5 institutional investors reported holding 2,317 shares of BRAINSTORM CELL THERAPEUTICS INC. - Common Stock, $0.00005 par value (BCLI). This represents 0.03% of the company’s total 7,182,182 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$188 | $0.58 | 0 |
| 2025 Q3 | 2,317 | $1,727 | -$261,340 | $0.71 | 5 |
| 2025 Q2 | 235,778 | $263,958 | -$804,996 | $1.12 | 33 |
| 2025 Q1 | 866,024 | $1,091,190 | +$799,421 | $1.26 | 31 |
| 2024 Q4 | 206,710 | $468,811 | +$407,283 | $2.27 | 29 |
| 2024 Q3 | 157,266 | $36,709 | +$36,712 | $0.23 | 4 |